Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Synthetic Genetic Codes Move Closer to Programmable Biology
Synthetic genetic codes are moving closer to programmable biology as automated cell-free systems enable faster testing of new protein chemistries in R&D.
Integrated Pharma Operations and Supply Chain Management
Pharma operations and supply chain management are converging with forecasting, manufacturing, resilience, and digitalisation of Technical Operations.
AI in GMP Manufacturing: Are Regulators Ready for Digital Factories?
Learn how AI in pharmaceutical GMP manufacturing is improving quality, data integrity, predictive maintenance, and regulatory compliance in modern drug production.
Endpoints in Gynaecological Oncology Clinical Trials
Gynaecological oncology clinical trials reveal that survival gains and trial design do not always align. Here is what clinical development teams should learn.
Nanocarriers Target the Eye for Better Ocular Drug Delivery
Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.